SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-023661
Filing Date
2022-08-22
Accepted
2022-08-22 09:12:47
Documents
57
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1428004
2 ex31-1.htm EX-31.1 10983
3 ex32-1.htm EX-32.1 4681
  Complete submission text file 0001493152-22-023661.txt   5667484

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE endv-20220630.xsd EX-101.SCH 42859
5 XBRL CALCULATION FILE endv-20220630_cal.xml EX-101.CAL 43519
6 XBRL DEFINITION FILE endv-20220630_def.xml EX-101.DEF 196523
7 XBRL LABEL FILE endv-20220630_lab.xml EX-101.LAB 360125
8 XBRL PRESENTATION FILE endv-20220630_pre.xml EX-101.PRE 266292
51 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 881937
Mailing Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367
Business Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367 (800) 489-4774
ENDONOVO THERAPEUTICS, INC. (Filer) CIK: 0001528172 (see all company filings)

IRS No.: 452552528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-55453 | Film No.: 221182378
SIC: 2834 Pharmaceutical Preparations